Scinai Immunotherapeutics

Company Overview

Snapshot

Founded in July 2003, Scinai Immunotherapeutics operates with 11–50 employees and has raised a total of $63.94 million across 12 funding rounds. The company was acquired by Pincell srl in June 2025, marking a significant strategic development in its trajectory.

Business overview

Scinai Immunotherapeutics is a biopharmaceutical company dedicated to the development, manufacturing, and commercialization of innovative inflammation and immunology (I&I) biological products. The company primarily targets autoimmune and infectious diseases, leveraging a state-of-the-art facility for biopharmaceutical product development and manufacturing. Scinai offers end-to-end boutique CDMO services while advancing its own pipeline of diversified and commercially viable products, including an innovative nanosized VHH antibody (NanoAb) pipeline addressing diseases with significant unmet medical needs. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Drugs Discovery & Development, serving healthcare providers and patients.

Strategic signal

In February 2026, Scinai Immunotherapeutics announced expanded support from the Israel Innovation Authority for its robotic aseptic fill & finish platform, securing a grant of NIS 5 million over two years. This investment is crucial for enhancing Scinai's Contract Development and Manufacturing Organization (CDMO) capabilities, particularly following its acquisition of Recipharm Israel Ltd. and a strategic collaboration with Recipharm. This development signals a strong commitment to modernizing manufacturing processes, reducing human intervention, and improving contamination control, positioning Scinai as a key player in advanced biopharmaceutical production and strengthening its competitive edge in the CDMO market.

Company Intelligence Q&A

What was a significant recent development for Scinai Immunotherapeutics?

Scinai Immunotherapeutics was acquired by Pincell srl in June 2025, marking a key exit event for the company.

What strategic reorganization did Scinai Immunotherapeutics complete in April 2026?

In April 2026, Scinai completed a strategic reorganization to establish a dedicated CDMO platform and a lean R&D structure, outlining its priorities for 2026.

What was the outcome of the financial results reported by Scinai Immunotherapeutics in April 2026?

In April 2026, Scinai reported its full-year 2025 results, highlighting that CDMO revenues doubled and noting strategic expansion through its collaboration with Recipharm.

What was the nature of the agreement Scinai Immunotherapeutics signed in March 2026?

In March 2026, Scinai signed a Second Amendment to its Binding Option Agreement for acquiring PinCell S.r.l. and submitted a revised application for €12 million in non-dilutive funding under the European Funds for the Modern Economy (FENG) SMART Path program to advance PC111 through human proof-of-concept.

What grant did Scinai Immunotherapeutics receive in February 2026?

In February 2026, Scinai Immunotherapeutics announced expanded support from the Israel Innovation Authority for its robotic aseptic fill & finish platform, receiving a grant totaling NIS 5 million over two years.